Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bard Expects Coated Endotracheal Tube In 2007, Recovery Aids Q1 Growth

This article was originally published in The Gray Sheet

Executive Summary

Bard will file a 510(k) for its anti-infection endotracheal tube in mid-2006 after conducting a 60-site, 1,700-patient clinical trial

You may also be interested in...



Mid-Sized Bard Delivers Solid Growth In Device Landscape Of Giants, Infants

Bard aims to rely on execution in niche areas where it can comfortably sustain market leadership to deliver sustainable double-digit revenue growth, according to President & CEO Tim Ring

Cosmetic And Personal Care Trademark Review: 9 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel